We claim:

1. A combination comprising a pure 5-HT_6 receptor antagonist, an acetylcholinesterase inhibitor and a NMDA receptor antagonist;
wherein:
the pure 5-HT_6 receptor antagonist is selected from the group consisting of:
1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole;
1-[(4-Fluorophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole;
and
1-[(4-Isopropylphenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole;
or a pharmaceutically acceptable salt thereof.

2. The combination as claimed in claim 1, wherein the acetylcholinesterase inhibitor is selected from the group consisting of donepezil, rivastigmine and galantamine or a pharmaceutically acceptable salt thereof.

3. The combination as claimed in claim 1 or 2, wherein the NMDA receptor antagonist is memantine or a pharmaceutically acceptable salt thereof.

4. The combination as claimed in any one of claims 1 to 3, wherein the pure 5-HT_6 receptor antagonist is 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof.

5. The combination as claimed in any one of the claims 1 to 4, wherein the pharmaceutically acceptable salt of the pure 5-HT_6 receptor antagonist is selected from
1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate;
1-[(4-Fluorophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dihydrochloride; and
1-[(4-Isopropylphenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dihydrochloride.

6. The combination as claimed in any one of the claims 1 to 5, wherein the pure 5-HT_6 receptor antagonist is 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate.

7. The combination as claimed in any one of the claims 1 to 6, wherein the acetylcholinesterase inhibitor is donepezil or a pharmaceutically acceptable salt thereof; or wherein the acetylcholinesterase inhibitor is donepezil hydrochloride.

8. The combination as claimed in any one of the claims 1 to 7, wherein the NMDA receptor antagonist is memantine hydrochloride.

9. A combination comprising 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate, donepezil hydrochloride and memantine hydrochloride.

10. The combination as claimed in any one of the claims 1 to 9, for use in the treatment of cognitive disorders in a patient.

11. Use of the combination as claimed in claim 10 in the manufacture of a medicament for the treatment of cognitive disorders in a patient, wherein the cognitive disorder is selected from Alzheimer's disease, schizophrenia, Parkinson's disease, Lewy body dementia, vascular dementia and frontotemporal dementia.

12. Use of a compound, 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof in combination with an acetylcholinesterase inhibitor and an NMDA receptor antagonist in the manufacture of a medicament for the treatment of Alzheimer's disease in a patient.

13. The use as claimed in claim 12, wherein the medicament is for an adjunct treatment in a patient on stable treatment with acetylcholinesterase inhibitor and NMDA receptor antagonist.

14. The use as claimed in claim 12 or claim 13, wherein the acetylcholinesterase inhibitor is selected from the group consisting of donepezil, rivastigmine and galantamine or a pharmaceutically acceptable salt thereof.

15. The use as claimed in any one of the claims 12 to 14, wherein the NMDA receptor antagonist is memantine or a pharmaceutically acceptable salt thereof.

16. The use as claimed in claim 12, (a) wherein 1 mg to 200 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is to be administered to a patient per day, or
(b) wherein 1 mg to 10 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is to be administered to a patient per day, or
(c) wherein 25 mg to 125 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is to be administered to a patient per day, or
(d) wherein 150 mg to 200 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is to be administered to a patient per day, or
(e) wherein 25 mg to 75 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is to be administered to a patient per day, or
(f) wherein 75 mg to 150 mg of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is to be administered to a patient per day; and
(g) wherein 1 mg to 30 mg of donepezil or a pharmaceutically acceptable salt thereof is to be administered to the patient per day; and
(h) wherein 1 mg to 40 mg of memantine or a pharmaceutically acceptable salt thereof is to be administered to the patient per day.

17. A pharmaceutical composition comprising the combination as claimed in any one of the claims 1 to 9, and pharmaceutically acceptable excipients.

18. The pharmaceutical composition as claimed in claim 17, for use in the treatment of cognitive disorders selected from Alzheimer's disease, schizophrenia, Parkinson's diseases, Lewy body dementia, vascular dementia and frontotemporal dementia.

19. The pharmaceutical composition as claimed in claim 17 or the pharmaceutical composition for use as claimed in claim 18, (a) wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is present in an amount of 1 mg to 300 mg, or
(b) wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is present in an amount of 35 mg to 200 mg, or
(c) wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is present in an amount of 200 mg to 300 mg, or
(d) wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is present in an amount of 75 mg to 150 mg, and
(e) wherein the donepezil or a pharmaceutically acceptable salt thereof is present in an amount of 2 mg to 30 mg, and
(f) wherein the memantine or a pharmaceutically acceptable salt thereof is present in an amount of 1 mg to 40 mg.

20. The use as claimed in claim 12, wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is to be administered to the patient by oral, nasal, local, dermal or parenteral routes.

21. The use as claimed in claim 12, wherein the 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof is to be administered to the patient one to three times per day, one to three times per week or one to three times per month.

22. Use of a combination as claimed in any one of claims 1 to 9; or of a compound, 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl) methyl]-1H-indole or a pharmaceutically acceptable salt thereof in combination with an acetylcholinesterase inhibitor and a NMDA receptor antagonist; or of a pharmaceutical composition as claimed in claim 17 in the manufacture of a medicament for the treatment of cognitive disorders in a patient.